MenuClose

CoGenesis™ Cancer

What is CoGenesis™ Cancer?

CoGenesis™ Cancer allows accurate molecular profiling of tumor tissues. With the use of next-generation sequencing, CoGenesis™ Cancer detects aberrations in cancer genes that are responsible for a wide range of cancers. Together with our actively growing pharmacogenomics database, CoGenesis™ Cancer provides valuable insights into the specific causes of each individual tumor, enabling clinicians to personalize treatment for cancer patients during routine oncology practice.

Why do we suggest CoGenesis™ Cancer?

Different from hereditary cancer screening, CoGenesis™ Cancer panel provides clinically actionable results for cancer patients

Benefits of CoGenesis™ Cancer

  • Provides tailored targeted therapy and immunotherapy suggestions
  • Reduces potential side effects, and shortens the time to recovery
  • Confirms the molecular subtype of tumors for more accurate clinical diagnosis

Who should consider CoGenesis™ Cancer test?

  • Patients who are considering targeted therapies or immunotherapies
  • Patients who are not responding well to conventional cancer therapies
  • Clinician’s request to classify the subtypes of the tumour for patient management

 

Evidences

  • CRC: pembrolizumab reported to have 72% 2-year overall survival in adults with treatment refractory metastatic mismatch repair-deficient colorectal cancer [1]
  • Lung cancer: first-line treatment with EGFR tyrosine kinase inhibitors is associated with improved progression free survival compared to platinum-based doublet chemotherapy in adults with EGFR mutation and stage IIIB-IV non-small cell lung cancer [2]. ROS1 gene must be performed in all lung adenocarcinoma. BRAF, RET, HER2, KRAS, MET should be tested if routine EGFR, ALK, and ROS1 testing are negative [3].
  • Breast cancer: Genetic testing should be made available to all newly diagnosed breast cancer patient. Testing should not be limited to BRCA1/2 [4]

 

Identify tumor type
(Multiclass Cancer Diagnosis)
Companion diagnostics
(Molecular Biomarker Diagnosis)

How to order the test?

CoGenesis™ Cancer is available from our partner’s clinics. Please contact us for more information.

Reference

[1] Dung T.L.E. et. al, A pan-cancer biomarker is identified that can predict successful response to cancer immunotherapy in human patients. Science, 2017; 28 JUL 2017 pp 409-413

[2] Gao G. et al ., Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials. Int. J. Cancer, 2012; 131: E822-E829

[3] Kalemkerian, G et. al., Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement Summary of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. Journal Of Oncology Practice, 2018; 14(5), 323-327

[4] The American Society of Breast Surgeon, Consensus Guideline on Genetic Testing for Hereditary Breast Cancer, 2018